FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  MILLER RICHARD A MD				2. Issuer Name and Ticker or Trading Symbol Bolt Biotherapeutics, Inc. [ BOLT ]					(Ch	eck all applic  X Directo	or	10	1% Ow	ner		
(Last) (First) (Middle) C/O BOLT BIOTHERAPEUTICS, INC. 900 CHESAPEAKE DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 12/14/2022							officer below)	(give title		her (s low)	ресіту	
(Street) REDWO CITY (City)	С.		94063 (Zip)	4.1	f Amer	ndment, I	Date (	of Original File	ed (Month/Da	ay/Year)	Line	e) <mark>X</mark> Form f	loint/Group I iled by One iled by More	Reporting	Persor	1
		Tab	le I - Non-De	erivativ	e Sec	curities	s Ac	quired, Di	sposed o	of, or Be	neficiall	y Owned				
Date			ransaction e onth/Day/Ye	Execution Date,		Code (Ins	de (Instr. 5)		tr. 3, 4 and	Beneficia Owned F Reported	s ally following	6. Ownersh Form: Dire (D) or Indir (I) (Instr. 4)	ct c	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s) and 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, Curity or Exercise (Month/Day/Year) if any		Code (	ansaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)  (Month/Day/Year)  7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owner Form Direct or Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$1.36	12/14/2022		A		25,000		(1)	12/13/2032	Common Stock	25,000	\$0.00	25,000		)	

## **Explanation of Responses:**

1. The shares subject to this option shall be fully vested upon grant date of December 14, 2022.

## Remarks:

/s/ William P. Quinn, Attorney-

in-Fact

\*\* Signature of Reporting Person Date

12/16/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.